On April 20, 2026 Enara Bio, a pioneer in Dark Antigen discovery and bispecific T cell engager (TCE) innovation, reported the presentation of new preclinical data for ENA101, its first‑in‑class bispecific T cell engager (TCE), delivered today in an oral session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ENA101 targets DARKFOX, a novel, cancer‑specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using Enara’s proprietary EDAPT platform and represents a new class of highly tumor‑specific targets derived from the dark proteome.
"ENA101 exemplifies the power of uncovering antigens within the dark proteome to overcome long-standing challenges in solid tumor immunotherapy," said Dr. Joe Dukes, Chief Scientific Officer of Enara Bio. "The data presented today at AACR (Free AACR Whitepaper) demonstrate that DARKFOX is a compelling cancer specific target and that ENA101 exhibits the potency, specificity and druglike profile required to advance a best-in-class T cell engager toward the clinic."
The oral presentation, titled "ENA101: A First‑in‑Class Bispecific T Cell Engager Targeting a DARKFOX Peptide Presented by Solid Tumors," was delivered by Dr. Joe Dukes in the Advances in Therapeutic Antibodies session
(Abstract #4052). The presentation highlighted the discovery of DARKFOX, the engineering of ENA101, and the comprehensive preclinical dataset supporting its advancement into clinical development.
Enara Bio is currently advancing ENA101 through IND-enabling studies to support IND filing in 2H’2026.
The abstract is available in Proceedings of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026.
About ENA101
ENA101 is a first‑in‑class bispecific T cell engager developed using Enara Bio’s proprietary EnTiCE platform. It incorporates a high‑affinity TCR‑mimic binder targeting the DARKFOX‑A3 peptide, a clinically validated anti‑CD3 arm, and an Fc‑based architecture for half‑life extension, to enable potent, selective and durable anti‑tumor immune responses.
(Press release, Enara Bio, APR 20, 2026, View Source [SID1234664592])